• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Mulhearn .

作者信息

Schäfer Martin, Strangfeld Anja, Hyrich Kimme L, Carmona Loreto, Gianfrancesco Milena, Lawson-Tovey Saskia, Mateus Elsa F, Gossec Laure, Robinson Philip C, Yazdany Jinoos, Machado Pedro M

机构信息

German Rheumatism Research Center (DRFZ Berlin), Epidemiology and Health Care Research, Berlin, Germany.

Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.

出版信息

Ann Rheum Dis. 2023 May;82(5):e116. doi: 10.1136/annrheumdis-2021-220134. Epub 2021 Mar 1.

DOI:10.1136/annrheumdis-2021-220134
PMID:33648957
Abstract
摘要

相似文献

1
Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Mulhearn .对Mulhearn所著《关于“风湿性疾病患者中与COVID-19相关死亡的因素：COVID-19全球风湿病联盟医生报告登记处的结果”的通信》的回应
Ann Rheum Dis. 2023 May;82(5):e116. doi: 10.1136/annrheumdis-2021-220134. Epub 2021 Mar 1.
2
Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Rosenbaum .对罗森鲍姆所著《关于“风湿性疾病患者中与COVID-19相关死亡的因素：COVID-19全球风湿病联盟医生报告登记处的结果”的通信》的回复
Ann Rheum Dis. 2023 Jun;82(6):e139. doi: 10.1136/annrheumdis-2021-220613. Epub 2021 May 13.
3
Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry' by Arnaud and Devilliers.对阿诺德和德维利耶斯的《关于“风湿性疾病患者中与COVID-19相关死亡的因素：COVID-19全球风湿病联盟医生报告登记处的结果”的通信》的回复
Ann Rheum Dis. 2023 May;82(5):e114. doi: 10.1136/annrheumdis-2021-220058. Epub 2021 Feb 18.
4
COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco . Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience' by Khan 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M by Andreica and 'COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs' by Ansarin .COVID-19全球风湿病联盟注册研究、抗白细胞介素-6治疗、共同决策与患者预后。对以下文章的回应：吉安弗朗切斯科撰写的“风湿病患者COVID-19住院相关特征：来自COVID-19全球风湿病联盟医生报告注册研究的数据”；汗撰写的“在临床试验出现之前，在严重COVID-19伴高炎症中同情使用托珠单抗——一家地区综合医院的真实世界经验”；安德烈伊卡撰写的“对吉安弗朗切斯科·M撰写的‘风湿病患者COVID-19住院相关特征：来自COVID-19全球风湿病联盟医生报告注册研究的数据’的评论”；安萨林撰写的“接受免疫调节药物治疗的系统性自身免疫疾病患者的COVID-19结局” 。
Ann Rheum Dis. 2022 Oct;81(10):e191. doi: 10.1136/annrheumdis-2020-218713. Epub 2020 Aug 12.
5
Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco . Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases' by Giollo .风湿性疾病活动、糖皮质激素使用与2019冠状病毒病。对以下内容的回应：“关于‘风湿性疾病患者2019冠状病毒病住院相关特征：来自2019冠状病毒病全球风湿病联盟医生报告登记处的数据’的通信”，作者为詹弗兰切斯科。乔洛指出：“在风湿性肌肉骨骼疾病患者中，疾病活动而非糖皮质激素治疗可能与2019冠状病毒病的严重程度相关。”
Ann Rheum Dis. 2022 Nov;81(11):e223. doi: 10.1136/annrheumdis-2020-218910. Epub 2020 Sep 7.
6
Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry'.关于“风湿性疾病患者中与COVID-19相关死亡的因素：COVID-19全球风湿病联盟医生报告登记处的结果”的通信
Ann Rheum Dis. 2023 May;82(5):e113. doi: 10.1136/annrheumdis-2021-220037. Epub 2021 Feb 18.
7
Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco . Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases.关于吉安弗兰切斯科所著《风湿性疾病患者新冠病毒肺炎住院相关特征：来自新冠病毒肺炎全球风湿病联盟医生报告登记处的数据》的通信。在风湿性肌肉骨骼疾病患者中，疾病活动度而非糖皮质激素治疗，可能与新冠病毒肺炎的严重程度相关。
Ann Rheum Dis. 2022 Nov;81(11):e222. doi: 10.1136/annrheumdis-2020-218845. Epub 2020 Sep 7.
8
Correspondence to: 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco .致信：吉安弗兰切斯科所著的《风湿病患者中与 COVID-19 住院相关的特征：来自 COVID-19 全球风湿病联盟医生报告登记处的数据》
Ann Rheum Dis. 2023 Jun;82(6):e140. doi: 10.1136/annrheumdis-2020-218733. Epub 2020 Aug 19.
9
Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry'.关于“风湿性疾病患者中与COVID-19相关死亡的因素：COVID-19全球风湿病联盟医生报告登记处的结果”的通信
Ann Rheum Dis. 2023 May;82(5):e115. doi: 10.1136/annrheumdis-2021-220099. Epub 2021 Mar 1.
10
Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco . Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience.关于吉安弗兰切斯科的《风湿性疾病患者新冠病毒肺炎住院相关特征：来自新冠病毒肺炎全球风湿病联盟医生报告登记处的数据》的通信。在临床试验出现之前，托珠单抗在伴有高度炎症的重症新冠病毒肺炎中的同情用药——一家地区综合医院的真实世界经验。
Ann Rheum Dis. 2022 Oct;81(10):e188. doi: 10.1136/annrheumdis-2020-218528. Epub 2020 Jul 30.

引用本文的文献

1
Associations of DMARDs with post-acute sequelae of COVID-19 in patients with systemic autoimmune rheumatic diseases: a prospective study.改善病情抗风湿药与系统性自身免疫性风湿病患者新冠病毒病急性后遗症的关联：一项前瞻性研究
Rheumatology (Oxford). 2024 Oct 1;63(10):2828-2837. doi: 10.1093/rheumatology/kead662.
2
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries.银屑病、银屑病关节炎和中轴型脊柱关节炎患者 COVID-19 结局不良的相关特征：COVID-19 PsoProtect 和全球风湿病联盟医生报告登记处的数据。
Ann Rheum Dis. 2023 May;82(5):698-709. doi: 10.1136/ard-2022-223499. Epub 2023 Feb 14.
3
COVID-19 admissions and mortality in patients with early inflammatory arthritis: results from a UK national cohort.COVID-19 住院患者和早期炎症性关节炎患者的死亡率：来自英国全国队列研究的结果。
Rheumatology (Oxford). 2023 Sep 1;62(9):2979-2988. doi: 10.1093/rheumatology/kead018.
4
Outcomes of COVID-19 in people with rheumatic and musculoskeletal disease in Ireland over the first 2 years of the pandemic.爱尔兰大流行前 2 年风湿和肌肉骨骼疾病患者的 COVID-19 结局。
Ir J Med Sci. 2023 Oct;192(5):2495-2500. doi: 10.1007/s11845-022-03265-7. Epub 2023 Jan 9.
5
Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.特发性炎性肌病患者发生严重 COVID-19 的相关因素：COVID-19 全球风湿病联盟医生报告登记处的研究结果。
RMD Open. 2022 Sep;8(2). doi: 10.1136/rmdopen-2022-002508.
6
Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents.家庭作为治疗 COVID-19 的新前沿：抗炎药物的案例。
Lancet Infect Dis. 2023 Jan;23(1):e22-e33. doi: 10.1016/S1473-3099(22)00433-9. Epub 2022 Aug 26.
7
Folic acid and methotrexate use and their association with COVID-19 diagnosis and mortality: a case-control analysis from the UK Biobank.叶酸和甲氨蝶呤的使用及其与 COVID-19 诊断和死亡率的关系：来自英国生物银行的病例对照分析。
BMJ Open. 2022 Aug 24;12(8):e062945. doi: 10.1136/bmjopen-2022-062945.
8
A prospective longitudinal study evaluating the influence of immunosuppressives and other factors on COVID-19 in autoimmune rheumatic diseases.一项评估免疫抑制剂及其他因素对自身免疫性风湿疾病中新冠病毒感染影响的前瞻性纵向研究。
BMC Rheumatol. 2022 Jun 14;6(1):32. doi: 10.1186/s41927-022-00264-0.
9
Looking ahead: giant-cell arteritis in 10 years time.展望未来：十年后的巨细胞动脉炎。
Ther Adv Musculoskelet Dis. 2022 May 24;14:1759720X221096366. doi: 10.1177/1759720X221096366. eCollection 2022.
10
Coronavirus Disease 2019 Outcomes Among Recipients of Anti-CD20 Monoclonal Antibodies for Immune-Mediated Diseases: A Comparative Cohort Study.接受抗CD20单克隆抗体治疗的免疫介导疾病患者的2019冠状病毒病结局：一项比较队列研究
ACR Open Rheumatol. 2022 Mar;4(3):238-246. doi: 10.1002/acr2.11386. Epub 2021 Dec 10.